Cabelletta Bio Slides 4.35% as Biotech Peers Hold Steady, Investors Await New Catalysts
Explore Cabaletta Bio’s sharp 4.35% drop, its $261M market cap, and potential T‑cell therapy upside—why investors await clearer catalysts.
- CABALETTA BIO INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read
